Stay updated with breaking news from Philippe Monteyne. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Frederic Chereau named Chairman of the Board - Seasoned entrepreneur, Dr Claudia Mitchell, appointed Non-executive Director PARIS, Oct. 20, 2022 /PRNewswire/ -- Coave Therapeutics
LSP and Bpifrance, through its InnoBio 2 Fund, co-led international investor syndicate Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In-Class immunotherapies
ExeVir, a Ghent, Belgium-based company developing single domain antibody therapies providing broad protection against viral infections, closed its Series A financing raising a total of US$50m. The financing, announced in March 2021, was led by Fund+ with participation from VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures and new investors SRIW, Noshaq, Vives IUF, SambrInvest, as well as several Belgian family offices. In conjunction with the funding, Caroline Thielen, Investment Manager at SRIW will join the Board of ExeVir Bio alongside Torsten Mummenbrauer, CEO of ExeVir Bio, Philippe Monte...
ExeVir Announces Close of US$50 million / EUR42 million Series A Financing - Extends Series A with additional EUR19 million led by Fund+ - Unique llama-derived VHH72-Fc antibody (XVR011) for potential treatment and prevention of Covid-19, ready to start first-in-human trials - XVR011 expected to be effective against SARS-Cov-2 and importantly its rapidly spreading variants and other Sarbecoviruses to emerge in the future News provided by Share this article Share this article GHENT, Belgium, March 16, 2021 /PRNewswire/ -- ExeVir, which is developing single domain antibody therapies providing b...